Cite
HARVARD Citation
Zimmer, A. et al. (2019). A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. Journal for immunotherapy of cancer. 7 (1), p. . [Online].